

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF VIRGINIA
RICHMOND DIVISION**

RAI STRATEGIC HOLDINGS, INC. and)
R.J. REYNOLDS VAPOR COMPANY)
Plaintiffs,) Civil Action No. 3:20-cv-257
v.)
JURY TRIAL DEMANDED
ALTRIA CLIENT SERVICES LLC; PHILIP)
MORRIS USA, INC.; ALTRIA GROUP, INC.;)
PHILIP MORRIS INTERNATIONAL INC.;)
and PHILIP MORRIS PRODUCTS S.A.)
Defendants.)

COMPLAINT FOR PATENT INFRINGEMENT

David M. Maiorana (VA Bar No. 42334)
Ryan B. McCrum
JONES DAY
901 Lakeside Ave.
Cleveland, OH 44114
Telephone: (216) 586-3939
Facsimile: (216) 579-0212
Email: dmaiorana@jonesday.com
Email: rbmccrum@jonesday.com

Anthony M. Insogna
JONES DAY
4655 Executive Drive
Suite 1500
San Diego, CA 92121
Telephone: (858) 314-1200
Facsimile: (844) 345-3178
Email: aminsogna@jonesday.com

Stephanie E. Parker
JONES DAY
1420 Peachtree Street, N.E.
Suite 800
Atlanta, GA 30309
Telephone: (404) 521-3939
Facsimile: (404) 581-8330
Email: searker@jonesday.com

John J. Normile
JONES DAY
250 Vesey Street
New York, NY 10281
Telephone: (212) 326-3939
Facsimile: (212) 755-7306
Email: jjnormile@jonesday.com

*Counsel for Plaintiffs
RAI Strategic Holdings, Inc. and
R.J. Reynolds Vapor Company*

Plaintiffs, RAI Strategic Holdings, Inc. (“RAI”) and R.J. Reynolds Vapor Company (“RJRV”) (collectively, “Plaintiffs”), for their Complaint against Altria Client Services LLC (“ACS”), Philip Morris USA, Inc. (“PM USA”), Altria Group, Inc. (“AGI”), Philip Morris International, Inc. (“PMI”), and Philip Morris Products S.A. (“PMP”) (collectively, “Defendants”) allege as follows:

THE PARTIES

1. RAI is a North Carolina corporation with its principal place of business located at 401 North Main Street, Winston-Salem, N.C. RAI is the assignee and sole owner of U.S. Patent Nos. 8,314,591 (the ““591 patent”) attached hereto as Exhibit A, 9,814,268 (the ““268 patent”) attached hereto as Exhibit B, 9,839,238 (the ““238 patent”) attached hereto as Exhibit C, 9,901,123 (the ““123 patent”) attached here to as Exhibit D, 9,930,915 (the ““915 patent”) attached hereto as Exhibit E, and 10,492,542 (the ““542 patent”) attached hereto as Exhibit F (collectively, the “Asserted Patents”).

2. RAI is the assignee of, and has the right to enforce (including for past infringement), each of the Asserted Patents.

3. RJRV is a North Carolina corporation with its principal place of business located at 401 North Main Street, Winston-Salem, N.C. RJRV is the exclusive licensee of the Asserted Patents.

4. Upon information and belief, ACS is a Virginia corporation with offices at 6601 West Broad Street, Richmond, Virginia 23230.

5. Upon information and belief, PM USA is a Virginia corporation with offices at 6601 West Broad Street, Richmond, Virginia 23230.

6. Upon information and belief, AGI is a Virginia corporation with offices at 6601 West Broad Street, Richmond, Virginia 23230.

7. Upon information and belief, AGI is the ultimate parent entity of ACS and PM USA.

8. Upon information and belief, PMI is a Virginia corporation with offices at 120 Park Avenue, New York, New York 10017.

9. Upon information and belief, PMI is the ultimate parent entity of PMP.

10. Upon information and belief, PMP is a societe anonyme duly existing under the laws of Switzerland with a corporate address at Quai Jeanrenaud 3, 2000 Neuchâtel, Switzerland.

JURISDICTION AND VENUE

11. This action involves federal statutory questions and claims arising under the laws of the United States. This Court has jurisdiction over the subject matter of this action, without regard to the amount in controversy, pursuant to 35 U.S.C. § 271, *et. seq.* and 28 U.S.C. §§ 1331 and 1338.

12. Personal jurisdiction exists over the Defendants ACS, PM USA, AGI, and PMI because they are Virginia corporations and ACS, PM USA, and AGI have their principal places of business in this District.

13. As a foreign corporation, personal jurisdiction exists over PMP at least by virtue of Federal Rule of Civil Procedure 4(k)(2). In addition, personal jurisdiction exists over PMP based on the fact that, upon information and belief, it is responsible for causing the tort of patent infringement to occur in Virginia and this District.

14. Venue is proper in this Court under 28 U.S.C. §§ 1391 and 1400(b). Defendants ACS, PM USA, AGI, and PMI are Virginia corporations, and thus reside in the District. In

addition, a substantial part of the events or omissions giving rise to this claim occur in the District. Finally, ACS, PM USA, and AGI have regular and established places of business in the District and, upon information and belief, have committed, induced, or contributed to acts of infringement in this District. One or more of the Defendants has been selling and continues to sell the infringing products in this District.

15. Venue is proper as to PMP by virtue of 28 U.S.C. §§ 1391(c)(3) and 1400(b) because it is a foreign corporation.

FACTUAL BACKGROUND

THE ASSERTED PATENTS

16. The '591 patent is directed to a charging case for a personal vaporizing inhaler. The United States Patent and Trademark Office ("USPTO") issued the '591 patent on November 20, 2012, with one independent claim, which recites:

1. A case, comprising:

 a first cradle adapted to hold a personal vaporizing unit, said personal vaporizing unit having dimensions approximating a smoking article;

 a battery;

 a first contact and a second contact, said first contact and said second contact forming an electrical contact with said personal vaporizing unit when said personal vaporizing unit is held by said first cradle, said first contact and said second contact conducting charge from said battery to said personal vaporizing unit to charge said personal vaporizing unit.

17. The '268 patent is directed to a tobacco-containing smoking article. The USPTO issued the '268 patent on November 4, 2017, with two independent claims, including Claim 16, which recites:

16. A tobacco-containing, electrically-powered smoking article comprising:

- (a) a tubular outer housing having a mouth-end and an end distal to the mouth-end, the housing comprising an opening adapted for intake of air into the smoking article;
- (b) an electrical power source within the outer housing;
- (c) a controller adapted for regulating current flow through the heater;
- (d) a rod-shaped carrier device removably engaged with the mouth-end of the outer housing and comprising a tubular mouth-end piece and a tubular cartridge with two open ends allowing air to flow therethrough, wherein the cartridge includes a tobacco material and an aerosol-generating material; and
- (e) an electrical resistance heater in contact with the tobacco material and the aerosol-generating material and adapted for heating at least a portion of the tobacco material and the aerosol-generating material.

18. The '238 patent is directed to a control body for an electronic smoking article.

The USPTO issued the '238 patent on December 12, 2017, with two independent claims, including Claim 19, which recites:

19. A control body for an electronic smoking article, the control body comprising:

an elongated shell with an interior, a proximal end, and an opposing distal end;

a coupler formed of an elongated body having a first end that forms a wall and that engages the proximal end of the shell and a second end that comprises a cavity configured to releasably engage a cartridge, wherein the coupler includes a pressure channel extending between a first end that is in fluid communication with the cavity and a second end that opens through the wall at the first end of the coupler, wherein the coupler includes an air inlet channel in fluid communication with the cavity and an air inlet aperture in an exterior surface of the coupler, and wherein the coupler has a longitudinal axis extending from the first end to the second end, and the first end of the pressure channel is spatially separated from the air inlet channel relative to the longitudinal axis of the coupler; and

a microprocessor.

19. Plaintiffs have virtually marked and continue to virtually mark the '238 patent at www.vusevapor.com/patents, pursuant to 35 U.S.C. § 287(a).

20. The '123 patent is directed to a smoking article that includes an electrical power source that powers a heater to heat aerosol-forming material in a disposable portion of the

smoking article. The USPTO issued the '123 patent on February 27, 2018, with three independent claims, including Claim 27, which recites:

27. An electrically-powered, aerosol-generating smoking article comprising:
 - an electrical power source in the form of a battery within a tubular outer housing having a mouth-end and an end distal to the mouth-end;
 - at least one electrical resistance heater powered by said electrical power source, wherein at least a portion of the resistance heating element is elongated and extending downstream toward the mouth-end of the outer housing, the elongated portion of the resistance heating element positioned proximal to the center of the outer housing;
 - a controller within the tubular outer housing and adapted for regulating current flow through the electrical resistance heater; and
 - a cigarette-type device removably engaged with the mouth-end of the tubular outer housing and comprising a tobacco segment circumscribed by a wrapping material and comprising a tobacco material and an aerosol-forming material, wherein the elongated portion of the resistance heating element extends into the tobacco segment when the cigarette-type device is engaged with the mouth-end of the outer housing, such that during draw, aerosol-forming material can be volatilized to produce a visible mainstream aerosol incorporating tobacco components or tobacco-derived components that can be drawn into the mouth of the user of the smoking article.

21. Plaintiffs have virtually marked and continue to virtually mark the '123 patent at www.vusevapor.com/patents, pursuant to 35 U.S.C. § 287(a).

22. The '915 patent is directed to smoking articles and use thereof for yielding inhalation materials. The USPTO issued the '915 patent on April 3, 2018, with one independent claim, which recites:

1. A reusable control unit for use with a disposable smoking article, the reusable control unit comprising a control housing including:
 - a receiving end for receiving an engaging end of the disposable smoking article and having an electrical energy source that includes a projection extending outwardly therefrom and that includes a component that forms an electrical connection with electrical contacts on a separate electrical heating member; and

a control unit section that houses a power source, a switching component that actuates flow of electrical current from the electrical energy source to the electrical heating member, and a flow regulating component that regulates a previously initiated current flow from the electrical energy source to the electrical heating member, wherein the component that forms an electrical connection with the electrical contacts is located on the projection.

23. Plaintiffs have virtually marked and continue to virtually mark the '915 patent at www.vusevapor.com/patents, pursuant to 35 U.S.C. § 287(a).

24. The '542 patent is directed to smoking articles and use thereof for yielding inhalation materials. The USPTO issued the '542 patent on December 3, 2019, with two independent claims, including claim 1, which recites:

1. A smoking article for receiving a disposable aerosol forming substance, the smoking article comprising:

a housing having a proximal end for receiving the disposable aerosol forming substance and an opposite distal end;

a power source arranged within the housing adjacent to the distal end;

a receiving chamber formed at the proximal end of the housing and having an opening for receiving the disposable aerosol forming substance;

a heating projection extending at least partially in the receiving chamber towards the proximal end of the housing and terminating at a free end which is configured to be inserted into the disposable aerosol forming substance for heating the disposable aerosol forming substance, the heating projection comprising:

a heating member comprising an electrically resistive metal which is configured to heat the disposable aerosol forming substance;

an electrical connector for providing a flow of electricity to the heating member for heating the heating member; and

a control circuit positioned within the housing between the power source and the heating projection and connecting the heating member of the heating projection to the power source.

THE ACCUSED PRODUCTS

25. Defendants have developed a heat-not-burn tobacco system called IQOS®. The IQOS® system includes an electrically powered smoking article that comprises an IQOS® holder, a disposable tobacco stick, and a charger.

26. Defendants use, offer to sell, and sell the IQOS® system in United States, and import that system into the United States. For example, Defendants use, offer to sell, and sell the IQOS® system from a store that they own and operate in Atlanta, Georgia, since at least October 2019, and from a store they own in this District (on information and belief, at 3402 W. Cary St. in the Carytown district of Richmond) since approximately November 2019. In addition, Defendants have sold the infringing tobacco sticks to retailers in both Atlanta, Georgia and in this District, which retailers sell those products to consumers. The packaging for the IQOS® device Defendants sell in the United States recites: “Manufactured for Philip Morris USA, Richmond, VA. Made in Malaysia.” The packaging for the disposable tobacco sticks states: “Mfd. for Philip Morris USA, Richmond, VA. Made in Italy.”

27. The IQOS® holder is a rechargeable and reusable power unit that includes a casing or housing, control electronics, a battery as its electrical source, and a heating blade that heats using a regulated current flow from the battery to produce heat through resistance. The heater can be turned on using a pushbutton activated switch and turns off after a certain amount of time. The IQOS® holder has an end for receiving the tobacco stick. It is a tubular product, and its dimensions approximate the dimensions of a smoking article. The IQOS® holder has a circuit board that includes a projection extending outwardly therefrom and that includes a component that forms an electrical connection with electrical contacts on a separate electrical heating member.

28. The disposable tobacco stick is rod-shaped and is specially designed and intended for exclusive use with the IQOS® holder. The tobacco stick contains specially processed tobacco made from tobacco powder that has been reconstituted into sheets following the addition of water, glycerin, guar gum, and cellulose fibers. The IQOS® tobacco stick is sold in different flavors, including regular and menthol flavors (Smooth Menthol with 1.25 mg menthol per stick and Fresh Menthol with 2.5 mg menthol per stick) to satisfy different consumer preferences. The structure and operation across the variety of sticks is otherwise the same. The IQOS® tobacco stick is specifically designed to function with the IQOS® holder to produce an aerosol. Users inhale through the mouth-end of a filter on the IQOS® tobacco stick. The IQOS® tobacco stick is also marketed in conjunction with the Marlboro™ brand and is sometimes referred to as a HeatStick or Marlboro™ HeatStick.

29. The IQOS® system also includes an IQOS® charger for charging and storing the IQOS® holder after each use and an AC power adaptor for recharging the charger. The charger contains its own battery that contacts the IQOS® holder for charging.

30. Neither the IQOS® holder, nor the tobacco stick, nor the IQOS® charger is a staple article or commodity of commerce suitable for substantial non-infringing use. Instead, they are authorized by the United States Food and Drug Administration (“FDA”) solely and exclusively for use as part of the IQOS® system and are marketed and sold by Defendants solely and exclusively for use as part of the IQOS® system.

31. The IQOS® holder constitutes a material part of the invention claimed in all the Asserted Patents. The IQOS® charger constitutes a material part of the invention claimed in at least the '591 patent. The tobacco stick constitutes a material part of the invention claimed in at least the '268 and '123 patents.

32. Defendants sell the IQOS® charger, IQOS® holder, and tobacco stick in a kit that also contains a tool designed for cleaning the IQOS® holder. The IQOS® tobacco sticks are also sold separately, in, for example, packs of 20 for exclusive use with the IQOS® system.

33. Defendants are offering for sale and selling the IQOS® system with a User Guide and Quick Start Guide, both of which instruct end users to operate the IQOS® system in a way that infringes the Asserted Patents.

34. Upon information and belief, Defendants' customers, distributors, or resellers, as well as end users of the IQOS® system demonstrate or operate the IQOS® system in the United States in accordance with the IQOS® User Guide and Quick Start Guide that are included with the IQOS® system.

35. The IQOS® system works as follows: The user inserts a tobacco stick into the holder and turns on the device by means of the pushbutton activated switch. The switch signals to the control electronics, which cause the battery to produce and supply electrical current to the heating blade. The blade heats the aerosol-forming materials in the tobacco stick, generating an inhalable nicotine-containing aerosol for the user. The temperature of the heating blade is controlled so that its operating temperature does not exceed 350°C. This allows for heating of the tobacco constituents below the level of combustion, while producing a visible aerosol containing water, glycerin and nicotine.

36. Upon information and belief, ACS is licensed to distribute, offer to sell, and sell the IQOS® system and the corresponding tobacco sticks in the U.S., and it started doing so at least as early as October 2019.

37. Upon information and belief, PM USA is licensed to distribute, offer to sell, and sell the IQOS® system and the corresponding tobacco sticks in the U.S., and it started doing so at

least as early as October 2019. According to packaging materials submitted to the FDA and sold in the United States, the IQOS® system and components thereof are manufactured for PM USA.

38. Upon information and belief, PMI developed, and continues to develop, the IQOS® system.

39. Upon information and belief, PMP is the applicant for the pre-market tobacco application (“PMTA”) for the IQOS® system and is responsible for and controls the worldwide design, manufacturing and marketing of the IQOS® system, either directly or indirectly through its related entities, including manufacturing of the IQOS® system or components thereof in one or more of Switzerland, Italy, China, Malaysia, and/or Singapore for importation into the United States.

THE IMPORTATION, SALE, OFFER FOR SALE, AND DISTRIBUTION OF IQOS® DEVICES

40. Upon information and belief, on or around May 24, 2017, PMP, in concert with the other Defendants, filed PMTAs with FDA seeking approval to offer for sale and sell the IQOS® system in the United States.

41. On or around April 30, 2019, FDA announced that it had authorized the marketing and sale of the IQOS® system in the United States.

42. ACS and PM USA started importing, selling, offering for sale, and distributing IQOS® products in the United States at least as early as October 2019.

43. Upon information and belief, PMP manufactures portions or all of the IQOS® system for ACS and PM USA, and the IQOS® system is imported into the United States for sale and offer for sale after importation.

DEFENDANTS KNOW OF THE ASSERTED PATENTS, KNOW AND SPECIFICALLY INTEND THAT THE IQOS® PRODUCTS INFRINGE THE ASSERTED PATENTS, AND KNOW THAT THE IQOS® PRODUCTS ARE ESPECIALLY MADE OR ESPECIALLY ADAPTED FOR USE IN INFRINGING THE ASSERTED PATENTS

44. Upon information and belief, Defendants know of the Asserted Patents. *First*, upon information and belief, Defendants regularly survey the patent literature—and especially that of their competitors—for relevant patents and have encountered the Asserted Patents. *Second*, this complaint informs Defendants about the Asserted Patents. *Third*, some of the Defendants have cited the Asserted Patents during prosecution of their own patents. ACS cited the '591 patent while prosecuting its U.S. Patent No. 10,123,566 and its U.S. Design Patent No. D844,221 (the “'221 patent”); it cited U.S. Patent No. 7,726,320 (the “'320 patent”), the ancestor of both the '268 and '123 patents, during prosecution of its '221 patent and its U.S. Patent No. 10,258,087 (the “'087 patent”); and it cited U.S. Patent No. 9,078,473 (the “'473 patent”), the parent of the '915 patent, during prosecution of its U.S. Patent No. 10,278,424. PMP cited both the '320 and '473 patents during prosecution of its U.S. Patent No. 10,206,428; and it cited U.S. Patent publication No. 2017/0020200, which corresponds to the '123 patent, during prosecution of its U.S. Patent No. 9,986,767. Defendant ACS cited the U.S. publication of the '238 patent (U.S. Patent Application Publication No. 2015/0245658) during prosecution of its U.S. Patent Nos. D870,375 and 10,021,910. Moreover, Plaintiffs have virtually marked and continue to virtually mark the '123, '915, and '238 patents.

45. Upon information and belief, Defendants know and specifically intend that their actions—including providing the User Guide and Quick Start Guide with their products—induce actual infringement of the Asserted Patents. First, upon information and belief, Defendants analyze whether they have freedom to operate and therefore have considered whether their

actions induce others to infringe the Asserted Patents. Second, this complaint informs Defendants that their actions induce infringement.

46. Upon information and belief, Defendants know that each of the elements in the IQOS® system is especially made or especially adapted for use in an infringement of the Asserted Patents and is not a staple article or commodity of commerce suitable for substantial noninfringing use. First, upon information and belief, Defendants analyze whether they have freedom to operate and therefore have considered whether their actions contribute to others infringing the Asserted Patents. Second, this complaint informs Defendants of their infringement.

COUNT ONE
INFRINGEMENT OF U.S. PATENT NO. 8,314,591

47. Plaintiffs reallege, adopt, and incorporate by reference the allegations included within paragraphs 1 through 46 as if fully set forth herein.

48. The USPTO thoroughly examined the '591 patent. It is currently in force and presumed valid.

49. Defendants import, sell, offer for sale, and/or distribute the IQOS® system in the United States.

50. Upon such importation, sale, offer for sale, and/or distribution in the United States, Defendants directly infringe, induce others to infringe, and contribute to the infringement by others of at least claims 1, 2, and 7 of the '591 patent under 35 U.S.C. § 271(a), (b), and (c) in this Judicial District and elsewhere.

51. Plaintiffs have been and continue to be damaged by Defendants' infringement of these claims.

52. Plaintiffs have suffered and continue to suffer irreparable harm with no adequate remedy at law unless this Court enjoins Defendants and their agents, servants, employees, attorneys, representatives, and all others acting on their behalf from directly infringing, inducing infringement, and/or contributing to infringement of the '591 patent.

53. The balance of hardships favors an injunction, and such injunction would not disserve the public interest.

54. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek enhanced damages under 35 U.S.C. § 284.

55. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek attorneys' fees and costs under 35 U.S.C. § 285.

56. Therefore, Plaintiffs seek a judgment that Defendants directly infringe, induce infringement of, and contribute to infringement of at least claims 1, 2, and 7 of the '591 patent by the importation, sale, offer for sale, and distribution in the United States of the IQOS® system.

COUNT TWO
INFRINGEMENT OF U.S. PATENT NO. 9,814,268

57. Plaintiffs reallege, adopt, and incorporate by reference the allegations included within paragraphs 1 through 56 as if fully set forth herein.

58. The USPTO thoroughly examined the '268 patent. It is currently in force and presumed valid.

59. Defendants import, sell, offer for sale, and/or distribute the IQOS® system in the United States.

60. Upon such importation, sale, offer for sale, and/or distribution in the United States, Defendants directly infringe, induce others to infringe, and contribute to the infringement

by others of at least claims 16 and 17 of the '268 patent under 35 U.S.C. § 271(a), (b), and (c) in this Judicial District and elsewhere.

61. Plaintiffs have been and continue to be damaged by Defendants' infringement of these claims.

62. Plaintiffs have suffered and continue to suffer irreparable harm with no adequate remedy at law unless this Court enjoins Defendants and their agents, servants, employees, attorneys, representatives, and all others acting on their behalf from directly infringing, inducing infringement, and/or contributing to infringement of the '268 patent.

63. The balance of hardships favors an injunction, and such injunction would not disserve the public interest.

64. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek enhanced damages under 35 U.S.C. § 284.

65. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek attorneys' fees and costs under 35 U.S.C. § 285.

66. Therefore, Plaintiffs seek a judgment that Defendants directly infringe, induce infringement of, and contribute to infringement of at least claims 16 and 17 of the '268 patent by the importation, sale, offer for sale, and distribution in the United States of the IQOS® system.

COUNT THREE
INFRINGEMENT OF U.S. PATENT NO. 9,839,238

67. Plaintiffs reallege, adopt, and incorporate by reference the allegations included within paragraphs 1 through 66 as if fully set forth herein.

68. The USPTO thoroughly examined the '238 patent. It is currently in force and presumed valid.

69. Defendants import, sell, offer for sale, and/or distribute the IQOS® system in the United States.

70. Upon such importation, sale, offer for sale, and/or distribution in the United States, Defendants directly infringe, induce others to infringe, and contribute to the infringement by others of at least claim 19 of the '238 patent under 35 U.S.C. § 271(a), (b), and (c) in this Judicial District and elsewhere.

71. Plaintiffs have been and continue to be damaged by Defendants' infringement of these claims.

72. Plaintiffs have suffered and continue to suffer irreparable harm with no adequate remedy at law unless this Court enjoins Defendants and their agents, servants, employees, attorneys, representatives, and all others acting on their behalf from directly infringing, inducing infringement, and/or contributing to infringement of the '238 patent.

73. The balance of hardships favors an injunction, and such injunction would not disserve the public interest.

74. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek enhanced damages under 35 U.S.C. § 284.

75. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek attorneys' fees and costs under 35 U.S.C. § 285.

76. Therefore, Plaintiffs seek a judgment that Defendants directly infringe, induce infringement of, and contribute to infringement of at least claim 19 of the '238 patent by the importation, sale, offer for sale, and distribution in the United States of the IQOS® system.

COUNT FOUR
INFRINGEMENT OF U.S. PATENT NO. 9,901,123

77. Plaintiffs reallege, adopt, and incorporate by reference the allegations included within paragraphs 1 through 76 as if fully set forth herein.

78. The USPTO thoroughly examined the '123 patent. It is currently in force and presumed valid.

79. Defendants import, sell, offer for sale, and/or distribute the IQOS® system in the United States.

80. Upon such importation, sale, offer for sale, and/or distribution in the United States, Defendants directly infringe, induce others to infringe, and contribute to the infringement by others of at least claims 27-30 of the '123 patent under 35 U.S.C. § 271(a), (b), and (c) in this Judicial District and elsewhere.

81. Plaintiffs have been and continue to be damaged by Defendants' infringement of these claims.

82. Plaintiffs have suffered and continue to suffer irreparable harm with no adequate remedy at law unless this Court enjoins Defendants and their agents, servants, employees, attorneys, representatives, and all others acting on their behalf from directly infringing, inducing infringement, and/or contributing to infringement of the '123 patent.

83. The balance of hardships favors an injunction, and such injunction would not disserve the public interest.

84. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek enhanced damages under 35 U.S.C. § 284.

85. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek attorneys' fees and costs under 35 U.S.C. § 285.

86. Therefore, Plaintiffs seek a judgment that Defendants directly infringe, induce infringement of, and contribute to infringement of at least claims 27-30 of the '123 patent by the importation, sale, offer for sale, and distribution in the United States of the IQOS® system.

COUNT FIVE
INFRINGEMENT OF U.S. PATENT NO. 9,930,915

87. Plaintiffs reallege, adopt, and incorporate by reference the allegations included within paragraphs 1 through 86 as if fully set forth herein.

88. The USPTO thoroughly examined the '915 patent. It is currently in force and presumed valid.

89. Defendants import, sell, offer for sale, and/or distribute the IQOS® system in the United States.

90. Upon such importation, sale, offer for sale, and/or distribution in the United States, Defendants directly infringe, induce others to infringe, and contribute to the infringement by others of at least claims 1, 2, and 5 of the '915 patent under 35 U.S.C. § 271(a), (b), and (c) in this Judicial District and elsewhere.

91. Plaintiffs have been and continue to be damaged by Defendants' infringement of these claims.

92. Plaintiffs have suffered and continue to suffer irreparable harm with no adequate remedy at law unless this Court enjoins Defendants and their agents, servants, employees, attorneys, representatives, and all others acting on their behalf from directly infringing, inducing infringement, and/or contributing to infringement of the '915 patent.

93. The balance of hardships favors an injunction, and such injunction would not disserve the public interest.

94. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek enhanced damages under 35 U.S.C. § 284.

95. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek attorneys' fees and costs under 35 U.S.C. § 285.

96. Therefore, Plaintiffs seek a judgment that Defendants directly infringe, induce infringement of, and contribute to infringement of at least claims 1, 2, and 5 of the '915 patent by the importation, sale, offer for sale, and distribution in the United States of the IQOS® system.

COUNT SIX
INFRINGEMENT OF U.S. PATENT NO. 10,432,542

97. Plaintiffs reallege, adopt, and incorporate by reference the allegations included within paragraphs 1 through 96 as if fully set forth herein.

98. The USPTO thoroughly examined the '542 patent. It is currently in force and presumed valid.

99. Defendants import, sell, offer for sale, and/or distribute the IQOS® system in the United States.

100. Upon such importation, sale, offer for sale, and/or distribution in the United States, Defendants directly infringe, induce others to infringe, and contribute to the infringement by others of at least claims 1-30 of the '542 patent under 35 U.S.C. § 271(a), (b), and (c) in this Judicial District and elsewhere.

101. Plaintiffs have been and continue to be damaged by Defendants' infringement of these claims.

102. Plaintiffs have suffered and continue to suffer irreparable harm with no adequate remedy at law unless this Court enjoins Defendants and their agents, servants, employees,

attorneys, representatives, and all others acting on their behalf from directly infringing, inducing infringement, and/or contributing to infringement of the '542 patent.

103. The balance of hardships favors an injunction, and such injunction would not disserve the public interest.

104. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek enhanced damages under 35 U.S.C. § 284.

105. Defendants' infringement has been and continues to be deliberate, willful, and unlicensed, permitting Plaintiffs to seek attorneys' fees and costs under 35 U.S.C. § 285.

106. Therefore, Plaintiffs seek a judgment that Defendants directly infringe, induce infringement of, and contribute to infringement of at least claims 1-30 of the '542 patent by the importation, sale, offer for sale, and distribution in the United States of the IQOS® system.

PRAYER FOR RELIEF

Plaintiffs respectfully pray for the following relief:

- A. That the Court adjudge and decree that Defendants have infringed and are infringing the Asserted Patents;
- B. That the Court adjudge and decree that Defendants have contributed to and induced infringement and are actively contributing to and inducing infringement of the Asserted Patents;
- C. That the Court enter preliminary and permanent injunctions enjoining Defendants, their officers, employees, agents, and all others acting in concert with them or participating with them from further acts that infringe the Asserted Patents;

D. That the Court enter permanent and preliminary injunctions enjoining Defendants, their officers, employees, agents, and all others acting in concert with them or participating with them from actively contributing to or inducing others to infringe the Asserted Patents;

E. That Defendants be ordered by this Court to account for and pay to Plaintiffs damages adequate to compensate Plaintiffs for Defendants' infringement, contribution to, and inducement of infringement of the Asserted Patents;

F. That the Court treble the damages for Defendants' willful infringement of the Asserted Patents;

G. That the Court award pre-judgment interest on the damages;

H. That the Court declare this an exceptional case under 35 U.S.C. § 285;

I. That the Court award Plaintiffs their costs and attorneys' fees incurred in this action; and

J. That the Court award such other relief as it deems just and proper.

JURY DEMAND

Plaintiffs request a trial by jury on all issues so triable.

Dated: April 9, 2020

Respectfully submitted,



Stephanie E. Parker
JONES DAY
1420 Peachtree Street, N.E.
Suite 800
Atlanta, GA 30309
Telephone: (404) 521-3939
Facsimile: (404) 581-8330
Email: searker@jonesday.com

David M. Maiorana (VA Bar No. 42334)
Ryan B. McCrum
JONES DAY
901 Lakeside Ave.
Cleveland, OH 44114
Telephone: (216) 586-3939
Facsimile: (216) 579-0212
Email: dmaiorana@jonesday.com
Email: rbmccrum@jonesday.com

Anthony M. Insogna
JONES DAY
4655 Executive Drive
Suite 1500
San Diego, CA 92121
Telephone: (858) 314-1200
Facsimile: (844) 345-3178
Email: aminsogna@jonesday.com

John J. Normile
JONES DAY
250 Vesey Street
New York, NY 10281
Telephone: (212) 326-3939
Facsimile: (212) 755-7306
Email: jjnormile@jonesday.com

*Counsel for Plaintiffs
RAI Strategic Holdings, Inc.
R.J. Reynolds Vapor Company*